Francis Ssali
ID: UNCST-2021-R012134
|
Protocol A5394: “Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with both Chronic Hepatitis B and HIV” Version 1.0, May 27, 2022
REFNo: HS2647ES
1.2 Primary Objectives
1.2.1 To assess the safety and tolerability of treatment with SLGN administered once weekly by mouth for 24 weeks.
1.2.2 To determine the proportion of participants with ?1 log10 IU/mL decline in quantitative HBsAg (qHBsAg) after SLGN treatment at Week 24.
1.3 Secondary Objectives
1.3.1 To determine the proportion of participants with ?1 log10 IU/mL decline in qHBsAg at any time during the study after SLGN treatment initiation.
1.3.2 To determine the proportion of participants with ?0.5 log10 IU/mL decline in qHBsAg after SLGN treatment at Week 24.
1.3.3 To determine the proportion of participants with ?0.5 log10 IU/mL decline in qHBsAg at any time during the study after SLGN treatment initiation.
1.3.4 To evaluate the proportion of participants who achieve HBsAg loss after SLGN initiation and who sustain HBsAg loss during follow-up.
1.3.5 To evaluate changes in qHBsAg levels at Weeks 4, 12, 24, 36, and 48 after SLGN initiation and, separately, among the placebo recipients.
1.3.6 To determine the proportion of HBeAg positive participants at baseline who lose HBeAg at any time during the study, by study arm.
1.3.7 To determine the proportion of anti-HBe negative participants at baseline who develop anti-HBe at any time during the study, by study arm.
1.3.8 To determine the proportion of hepatitis B surface antibody (anti-HBs) negative participants at baseline who develop anti-HBs at any time during the study, by study arm.
1.3.9 To evaluate levels of circulating cytokines, including IFN-gamma, IL-12p40, IL-1RA, and CD163 at entry, 24 hours post-first study drug dose, Weeks 4, 12, 24, 36, and 48, by study arm.
1.3.10 To determine whether administration of SLGN will perturb HIV latency as measured by an increase in HIV transcription.
1.3.11 To determine whether administration of SLGN will decrease the size of the latent reservoir, as measured by the change in amount of cell-associated unspliced HIV RNA, HIV DNA, replication-competent and/or intact virus at Weeks 2, 4, 24, and 48.
1.4 Exploratory Objectives
1.4.1 To define the pharmacokinetic (PK) profile and PK-pharmacodynamic (PD) associations of SLGN in people with both HIV and CHB taking suppressive antiviral therapy for both viruses.
1.4.2 To explore if SLGN and antiretroviral (ARV) PK are altered when administered together.
1.4.3 To evaluate participants’ adherence by using several tools, including self-report, directly observed therapy (DOT), and drug concentrations.
1.4.4 To compare quantitative changes in experimental measures of HBV antiviral efficacy (including HBV RNA, hepatitis B core related antigen [HBcrAg], qHBeAg, and low positive HBsAg measured with a high sensitivity qHBsAg assay [LLOQ of 0.05 IU/mL]) and measure changes in large, medium, and small HBsAg isoforms from baseline during and after treatment.
1.4.5 To determine the immunological effects of SLGN on circulating immune signaling by performing single cell RNA sequencing using peripheral blood mononuclear cells (PBMCs) and evaluating HIV-specific T-cell responses.
1.4.6 To determine the effects on circulating immune cells, including cellular phenotypes and T and B-cell responses.
1.4.7 To determine whether administration of SLGN will affect levels of circulating cytokines, including TNF-alpha, IL-12, IL18, IP-10, ISG15, IL-21, Fas Ligand, and TRAIL.
|
Uganda |
2023-04-12 14:38:49 |
2026-04-12 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Alex Mwesigwa
ID:
|
P. falciparum genetic diversity, multiplicity of infection, gametocytaemia and recrudescence in areas of varied malaria transmission intensity in Uganda.
REFNo: HS2744ES
1. To compare the genetic diversity and multiplicity of P. falciparum infections in areas of varied malaria transmission intensity in Uganda.
2. To evaluate the relationship between malaria severity and P. falciparum genetic diversity, multiplicity of infection among patients living in areas of varied malaria transmission intensity in Uganda.
3. To investigate the temporal and seasonality changes in P. falciparum genetic diversity and multiplicity of infection among patients with malaria infection living in areas of varied malaria transmission intensity in Uganda.
4. To evaluate the performance of microsatellites in differentiating P. falciparum recrudescence from new infections.
|
Uganda |
2023-04-12 14:27:32 |
2026-04-12 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Jane Frances Zalwango
ID:
|
Etiopathogenesis of Blackwater Fever in Budaka District, Uganda: a pilot study
REFNo: HS2752ES
a)To explore the aetiology of BWF in Budaka District
b)To identify therapeutic interventions for the treatment of BWF
|
Uganda |
2023-04-12 14:23:40 |
2026-04-12 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Elizeus Rutebemberwa
ID: UNCST-2022-R009070
|
Evaluation of a Community Health Entrepreneur model in rural Uganda
REFNo: HS2196ES
4.3 General objective
To explore the role, reach, and scalability of CHE programme as a social franchise approach to address the issue of access to healthcare and potential embedment of the programme in the larger health system.
4.4 Specific objectives
1. To investigate health care seeking behaviour of residents in rural communities in Uganda, in order to assess community access, choice and use of health (care) services, service availability and quality, and experience of health care of households in villages in Uganda
2. To investigate the strengths and weaknesses of a CHE programme in communities which already have adopted this programme and the potential added value of a strengthened community health system by a CHE programme in communities without this programme
3. To investigate multi-stakeholder perceptions on the functioning, potential scale-up, and the possibility of integration of a social franchise approach in the larger health system in Uganda
|
Uganda |
2023-04-12 14:20:54 |
2026-04-12 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Isaac Ssewanyana
ID: UNCST-2020-R014336
|
Protocol for the establishment of clinical specimen panel for WHO Prequalification performance evaluation of HIV serology assays
REFNo: HS2786ES
To establish an HIV specimen repository at ITM.,To register the specimens into a Biobank at ITM; ,To characterize the specimens for HIV and syphilis serostatus using standardized reference assays and algorithms at ITM;,To collect biological specimens from patients with known HIV serostatus or blood donors from different regions of the world to establish a WHO HIV specimen evaluation panel that will be used for the laboratory performance evaluation of HIV serology assays undergoing WHO prequalification assessment; ,The overall objective is to assemble a new WHO HIV specimen evaluation panel in collaboration with PELs and collaborating centers, which will be made accessible on demand to all the PELs conducting HIV or dual HIV-syphilis serology test evaluations for WHO prequalification.,
|
Uganda |
2023-04-12 12:56:08 |
2026-04-12 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Edgar Mulogo Mugema
ID: UNCST-2023-R008170
|
Environmental Drivers of Pediatric Postinfectious Hydrocephalus in Western Uganda: Case-Control Study
REFNo: HS2699ES
The overarching objective of the study is to elucidate potential factors that underlie the ecological correlation between precipitation and PIH. Identification of these environmental intermediaries may elucidate potential targets for intervention to reduce the incidence of PIH.,
|
Uganda |
2023-04-11 15:42:30 |
2026-04-11 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
A multiple arm, multiple stage (MAMS), phase 2B/C, open label, randomized, controlled platform trial to evaluate experimental arms including an increased dose of rifampicin, an optimized dose of pyrazinamide, moxifloxacin and sutezolid, in adult subjects with newly diagnosed, smear-positive pulmonary tuberculosis
REFNo: HS2644ES
Primary Efficacy Objective:
Rifampicin- containing experimental arms (arms 1,2)
To evaluate whether one or more of two experimental regimens based on
optimized dose rifampicin, optimized dose of pyrazinamide, and moxifloxacin
given for 12, respectively 17 weeks, are superior to standard treatment given for
26 weeks, as assessed by time to sputum culture conversion to negative in liquid
media.
Sutezolid-containing experimental arm (arm 4)
? To evaluate whether the efficacy of an experimental regimen composed of
sutezolid, delamanid, bedaquiline, and moxifloxacin given for 17 weeks is
superior to standard treatment given for 26 weeks, as assessed by time to
sputum culture conversion to negative in liquid media.
Secondary Objectives This study’s secondary objectives are:
Efficacy
? To assess treatment efficacy based on proportion of patients with relapse
free outcome at 12 months after randomization.
? To assess treatment efficacy based on the rate of decline of bacterial load
measured by the Molecular Bacterial Load Assay
? To rank the relative efficacy of the experimental four-drug combinations
for the treatment of pulmonary tuberculosis within the first twelve weeks
of treatment, and select the most efficient experimental treatment
regimen or regimens for further development.
Safety and Tolerability
To assess the frequency, severity, and type of adverse events (AEs), and AErelated
treatment discontinuations.
Pharmacokinetics
To describe the pharmacokinetics of the drugs and doses used, and to assess
possible relationships between pharmacokinetic parameters of the various drugs and between pharmacokinetic parameters and participant characteristics.
Pharmacodynamics To describe relationships between pharmacokinetic parameters on the one hand and efficacy and safety endpoints on the other hand.
|
Uganda |
2023-04-11 15:27:11 |
2026-04-11 |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
.jpg)
|
Andrew Muhumuza
ID: UNCST-2022-R009010
|
Incidence and predictors of castration resistance among patients with prostate cancer on androgen deprivation therapy at two referral hospitals in Uganda
REFNo: HS2759ES
To identify the predictors of castration resistance among prostate cancer patients on ADT at Mbarara Referral Hospital oncology unit and Uganda cancer Institute, Mulago National Referral Hospital. ,To determine the incidence of castration resistance among patients with prostate cancer on ADT at Mbarara Referral Hospital oncology unit and Uganda cancer Institute, Mulago National Referral Hospital.,To determine the incidence and predictors of castration resistance among prostate cancer patients on ADT at Mbarara Referral Hospital oncology unit and Uganda cancer Institute, Mulago National Referral Hospital.,
|
Uganda |
2023-04-11 14:20:29 |
2026-04-11 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
SAM ALI
ID: UNCST-2020-R014824
|
Stillbirth in High Burden Settings: Ample Room for Improvement using Biomarkers and Ultrasound Technologies (iTECH)
REFNo: HS2762ES
1. To evaluate the relation between placental histopathological lesions and biomarkers, placenta ultrasound and hemodynamic changes after stillbirth and near miss stillbirth in order to understand the underlying mechanisms and specify the prediction model.
2. To engage with important stakeholders on the value of these diagnostic technologies in the community, co-creating the project design, implementation and eventual uptake into practice guidelines.
3. To establish the predictive performance of maternal characteristics and markers emerging from this project for stillbirth and other related endpoints in non-anomalous fetuses and assess the feasibility of integrating relevant markers into clinical decision support tools.
4. To prospectively evaluate patterns of (bio)markers, maternal cardiovascular function and contemporary ultrasound markers in pregnancy, to understand their role in the chain of events and pathophysiology of stillbirth in a resource poor setting.
5. To develop and validate a prediction model for use at the point of care in low-and middle-incomes countries (LMICs) to quantify a woman’s individual risk of antepartum stillbirth based on a set of easily measurable, accessible, highly predictive and cost-effective markers, and make it freely available for healthcare providers in low-resource settings.
|
Uganda |
2023-04-06 8:06:27 |
2026-04-06 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Juliana Namutundu
ID:
|
IMPROVING CERVICAL CANCER SCREENING LITERACY AMONG HIV-INFECTED WOMEN IN CARE AT RURAL PUBLIC HEALTH FACILITIES IN EAST CENTRAL UGANDA
REFNo: HS2753ES
3) To assess the feasibility, acceptability and preliminary effectiveness of a cervical cancer screening literacy improvement implementation strategy for Women living with HIV in care at rural public health facilities in East Central Uganda.,2) To design a cervical cancer screening literacy improvement implementation strategy for Women living with HIV in care at rural public health facilities in East Central Uganda.,1) To conduct a multi-level assessment of barriers and facilitators of cervical cancer screening literacy among HIV-infected women in care at rural public health facilities in East Central Uganda.,
|
Uganda |
2023-04-05 17:05:10 |
2026-04-05 |
Medical and Health Sciences |
Non-Clinical Trial |
Degree Award |
|
Margaret Nafuna Sarah
ID:
|
EXAMINING MOTIVATIONAL STRATEGIES INFLUENCING PERFORMANCE OF TUTORS IN CORE PRIMARY TEACHERS’ COLLEGES IN EASTERN UGANDA
REFNo: SS1647ES
3. To analyse the challenges that may influence the effective motivation of tutors in Core PTCs in Eastern Uganda.,2. To examine the views of tutors on how motivational strategies affect their performance in Core PTCs in Eastern Uganda.,1. To investigate motivational strategies employed in Core PTCS in Eastern Uganda. ,
|
Uganda |
2023-04-04 9:36:11 |
2026-04-04 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
.jpg)
|
Milcah Abasabyona
ID:
|
Intimacies of Identification and Lived Citizenship among the Ghetto Youths in Kampala, Uganda
REFNo: SS1654ES
Main Objective:
To investigate how citizen certification and identification influences levels of belonging to a place and space, impacts on citizen-state relationship and individual personhood.
Specific Objectives:
1. To capture the individual practical experiences of legal certification and identification processes among the Ghetto youths.
2. To examine the regulatory effects of identification documents on citizenship rights, a sense of belonging, and personhood among the Ghetto youths in Kampala.
3. To explore the different key Identification documents and their role in the day to day lives of the Ghetto Youths.
4. To trace the ways in which the undocumented Ghetto youths create alternative routes to lived citizenship and self-certification.
|
Uganda |
2023-04-04 9:32:41 |
2026-04-04 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
|
ANYASE AMAZA RONALD
ID: UNCST-2022-R009325
|
Development of a Natural Anti-Aflatoxin Product
REFNo: HS2692ES
To develop a prototype natural based anti-aflatoxin product made from Ugandan plants.,To establish a database of plants in Uganda with anti-aflatoxin potential,To determine the indigenous approaches of aflatoxin control in Uganda.,To develop a natural based anti-aflatoxin product ,
|
Uganda |
2023-04-03 21:04:19 |
2026-04-03 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Scovia Mbalinda Nalugo
ID: UNCST-2020-R014259
|
Professional Identity of Ugandan Nurses and Midwives: Exploring the understanding, Perceptions and Experiences among student Nurses and Midwives, Recent Graduates and Nurse Educators
REFNo: HS2712ES
Explore nurse and midwife top management in the ministry of health and nurses and midwives council perception and experiences fostering professional identity in nursing in the country.,3. Explore nurse and Midwife educators’ perceptions and experiences fostering professional identity in nursing and midwife at Mbarara University of Science and Technology and Makerere university,2. Explore challenges and barriers to professional identity formation at Mbarara University of Science and Technology and Makerere University,1. Describe the understanding of the professional identity of final year undergraduate nurses and midwives and recent graduates at Mbarara University of Science and Technology and Makerere University.,
|
Uganda |
2023-04-03 21:00:42 |
2026-04-03 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
zaina Nakabuye
ID:
|
Technology orientation and the export performance of SME exporting firms in Uganda.
REFNo: SS1472ES
2. To establish the relationship between knowledge absorptive capacity and export performance.
3. To examine the relationship between supply chain agility and export performance.
4. To investigate the moderation of knowledge absorptive capacity between technology orientation and export performance.
5. To investigate the moderation of supply chain agility between technology orientation and export performance.
|
Uganda |
2023-04-03 20:58:43 |
2026-04-03 |
Social Science and Humanities |
Non-Clinical Trial |
Degree Award |
.jpg)
|
Pooja Chitneni
ID: UNCST-2021-R012955
|
Development and assessment of an HIV disclosure intervention for men in Uganda - Aim 1
REFNo: HS2682ES
Aim 1. Identify the unique HIV disclosure needs and preferences among MWH to support HIV disclosure. ,
|
USA |
2023-04-03 20:55:31 |
2026-04-03 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Joseph Kirabira
ID: UNCST-2019-R001427
|
Prevalence of and factors associated with mental disorders and coping mechanisms among students at Busitema University.
REFNo: HS2700ES
To explore factors influencing mental disorders among students at Busitema UniversityTo explore the coping mechanisms used by students at Busitema University
|
Uganda |
2023-04-03 20:53:26 |
2026-04-03 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Andrew Mujugira
ID: UNCST-2019-R000871
|
Qualitative research to prepare for novel HIV prevention products
REFNo: HS1749ES
Define a preliminary strategy for the integration of novel PrEP products (e.g., injectable Cabotegravir, Dapivirine intravaginal ring, TFV/LNG intravaginal ring) into existing oral PrEP programs by conducting qualitative interviews with experts in novel PrEP products, oral PrEP programs, and end users.
To achieve this aim, we will conduct approximately 60 key informant interviews (KII) with: 1) clinical trialists leading studies of novel PrEP products, 2) oral PrEP program leaders in sub-Saharan Africa and 3) young women in Uganda who have decided not to use oral PrEP during recent PrEP studies.
|
Uganda |
2023-04-03 20:51:28 |
2026-04-03 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Waiswa Peter
ID: UNCST-2020-R014921
|
Prevalence of intestinal colonization by ESBL-producing Enterobacterales in neonates at Jinja Regional Referral Hospital
REFNo: HS2737ES
• To highlight the area of antibiotic resistance in neonates in this setting ,• To conduct a point-prevalence surveillance of ESBL-producing Enterobacterales in the neonatal unit at two specific time-points with two weeks apart.,The overall aim of this project is to create base-line data for future infection prevention control strategies in the area of newborn care at Jinja Referral Hospital.,
|
Uganda |
2023-04-03 20:49:30 |
2026-04-03 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Stella Maris Nanyonga
ID:
|
Optimizing antimicrobial use in the management of Upper Respiratory Tract Infections through antimicrobial stewardship in Community Pharmacy practice in Uganda; A patient centered approach
REFNo: HS2617ES
Primary Objectives
1. To assess the knowledge, attitude, and practice (KAP) towards self-medication among patients who visit community pharmacies for the management of Upper respiratory tract infections.
2. To explore the barriers and facilitators of self-medication in the community.
3. To explore prescriber views and understanding on the use of delayed prescribing in primary care.
Secondary Objectives
4.To evaluate the effectiveness of training and delayed prescribing intervention on antibiotic consumption among patients with URTI who visit community pharmacies.
5. To describe dispensing and prescribing patterns of pharmacy staff when managing patients with upper respiratory tract infections at the community pharmacy
|
Uganda |
2023-04-03 20:46:30 |
2026-04-03 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|